Most importantly, we have provided clinical evidence showing that the expression level of the lncRNA MIAT/HMGB1/IL6 axis is elevated in resistant NPC tumors, which is highly correlated with the poor survival of patients. The gene discussed is MIAT; the disease is nasopharyngeal carcinoma.